SABCS: Serum Hormones Can Help ID Benefit of Anastrozole
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 11, 2023 -- Serum hormone concentrations can help ascertain which women with breast cancer will benefit from anastrozole treatment, according to a study published online Dec. 6 in The Lancet Oncology to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in San Antonio.
Jack Cuzick, Ph.D., from Queen Mary University of London, and colleagues conducted a case-control study using data from the IBIS-II prevention trial involving postmenopausal women aged 40 to 70 years at high risk for breast cancer. Women were randomly assigned to receive anastrozole (1 mg/day, orally) or placebo daily for five years (1,920 and 1,944 women, respectively). In this preplanned study, the primary analysis was the impact of the baseline estradiol-to-sex hormone binding globulin (SHBG) ratio on development of all breast cancers.
Participants were followed for a median of 131 months, during which time there were 85 and 165 cases of breast cancer (4.4 and 8.5 percent) in the anastrozole and placebo groups, respectively. The researchers identified a trend of increasing breast cancer risk with increasing estradiol-SHBG ratio in the placebo group, but not in the anastrozole group. In the placebo group, but not in the anastrozole group, there was also a weaker effect observed for the testosterone-SHBG ratio. In quartiles 2, 3, and 4, but not 1, of the estradiol-SHBG ratio, a relative benefit of anastrozole was seen.
"Measuring serum hormone concentrations could be an inexpensive method to help clinicians differentiate which women will benefit most from use of aromatase inhibitor for the prevention of breast cancer," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Pandemic Had Temporary Negative Effect on Breast Cancer Screening
THURSDAY, May 30, 2024 -- The COVID-19 pandemic had a transient negative effect on breast cancer screening overall and a prolonged negative effect on follow-up screening...
Patient Characteristics Linked to Performance of AI Algorithm for DBT
THURSDAY, May 30, 2024 -- For analyzing negative screening digital breast tomosynthesis (DBT) examinations, patient characteristics influence the case and risk scores of an...
Chemo + Breast Cancer Combo Accelerates Functional Decline in Seniors
WEDNESDAY, May 29, 2024 -- The combination of breast cancer and chemotherapy contributes to accelerated functional decline in older women with early-stage breast cancer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.